Transcatheter Aortic Valves Implantation (TAVI) - Medical Devices Pipeline Assessment, 2018

  • ID: 4580439
  • Report
  • 187 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Admedus Ltd
  • Carena Healthcare Ltd
  • Direct Flow Medical Inc
  • HLT, Inc.
  • Medtronic plc
  • SAS Cormove
  • MORE
Transcatheter Aortic Valves Implantation (TAVI) - Medical Devices Pipeline Assessment, 2018

Summary

The Medical Devices sector report, “Transcatheter Aortic Valves Implantation (TAVI) - Medical Devices Pipeline Assessment, 2018" provides an overview of Transcatheter Aortic Valves Implantation (TAVI) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transcatheter Aortic Valves Implantation (TAVI) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by The team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Transcatheter Aortic Valves Implantation (TAVI) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Transcatheter Aortic Valves Implantation (TAVI) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Transcatheter Aortic Valves Implantation (TAVI) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Admedus Ltd
  • Carena Healthcare Ltd
  • Direct Flow Medical Inc
  • HLT, Inc.
  • Medtronic plc
  • SAS Cormove
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Transcatheter Aortic Valves Implantation (TAVI) Overview

3 Products under Development
3.1 Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Stage of Development
3.2 Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Territory
3.3 Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Regulatory Path
3.4 Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Estimated Approval Date
3.5 Transcatheter Aortic Valves Implantation (TAVI) - Ongoing Clinical Trials

4 Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products under Development by Companies
4.1 Transcatheter Aortic Valves Implantation (TAVI) Companies - Pipeline Products by Stage of Development
4.2 Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Stage of Development

5 Transcatheter Aortic Valves Implantation (TAVI) Companies and Product Overview
5.1 Admedus Ltd Company Overview
5.2 Aegis Surgical Limited Company Overview
5.3 AorTx, Inc. Company Overview
5.4 Arbor Surgical Technologies, Inc. Company Overview
5.5 Boston Scientific Corp Company Overview
5.6 Carena Healthcare Ltd Company Overview
5.7 Clemson University Company Overview
5.8 Colibri Heart Valve, LLC Company Overview
5.9 Daidalos Solutions BV Company Overview
5.10 Direct Flow Medical Inc (Inactive) Company Overview
5.11 DSM Dyneema BV Company Overview
5.12 Dura LLC Company Overview
5.13 Edwards Lifesciences Corp Company Overview
5.14 HLT, Inc. Company Overview
5.15 JC Medical, Inc. Company Overview
5.16 JenaValve Technology GmbH Company Overview
5.17 Mayo Clinic Company Overview
5.18 Medtronic plc Company Overview
5.19 Meril Life Sciences Pvt Ltd Company Overview
5.20 MicroPort Scientific Corp Company Overview
5.21 PolyNova Cardiovascular LLC (Inactive) Company Overview
5.22 RegenaGraft Company Overview
5.23 ReValve Med Inc Company Overview
5.24 SAS Cormove Company Overview
5.25 St. Jude Medical LLC Company Overview
5.26 Symetis SA Company Overview
5.27 Thubrikar Aortic Valve, Inc. Company Overview
5.28 University College London Company Overview
5.29 University of California San Francisco Company Overview
5.30 University of Cambridge Company Overview
5.31 University of Iowa Company Overview
5.32 Vascular Concepts Ltd Company Overview
5.33 Venus MedTech Company Overview
5.34 Xeltis AG Company Overview

6 Transcatheter Aortic Valves Implantation (TAVI) - Recent Developments
6.1 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value
6.2 May 31, 2018: JC Medical Announces First-in-Human Treatment with the Unique Transfemoral J-Valve TAVI Device for Aortic Regurgitation
6.3 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results
6.4 May 22, 2018: Treatment with Abbott s Portico Transcatheter Aortic Valve Showed Portico is Safe and Reduces Severe Aortic Stenosis at 30 Days in Real-World Setting
6.5 May 22, 2018: Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve
6.6 May 22, 2018: Admedus: TAVR Progress Continues With Filing of New Provisional Patents
6.7 May 21, 2018: Edwards Announces Key Events For EuroPCR 2018
6.8 May 17, 2018: MicroPort CardioFlow Releases One-year Clinical Outcome of VitaFlow
6.9 May 17, 2018: MicroPort CardioFlow Attends Fourth China Valve (Hangzhou) Meeting
6.10 May 16, 2018: Boston Scientific Announces Schedule of Presentations at EuroPCR 2018
6.11 May 16, 2018: Boston Scientific Announces Schedule of Presentations at EuroPCR 2018
6.12 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy
6.13 May 04, 2018: Colibri Heart Valve Continues Enrollment in Clinical Feasibility Study of Second-Generation TAVI System
6.14 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018
6.15 Apr 24, 2018: Edwards Lifesciences Announces First Quarter 2018 Financial Results
6.16 Apr 19, 2018: Admedus TAVR Gaining Momentum With New Patent Applications
6.17 Apr 10, 2018: Jena Valve Technology Continues CE Mark Study Treating Severe Aortic Stenosis with Next-Generation System; Patient Enrollment and Successful Implantations with the Everdur Pericardial Aortic Valve and Coronatix Delivery Catheter
6.18 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics
6.19 Mar 28, 2018: Boston Scientific Prevails In U.K. Edwards Lifesciences Litigation
6.20 Mar 23, 2018: JenaValve Technology Appoints Keith D Dawkins MD as Board Member
6.21 Mar 19, 2018: Colibri Heart Valve Advances Second-Generation TAVI System into Clinical Feasibility Study
6.22 Mar 12, 2018: Admedus TAVR Project Passes Testing Milestone
6.23 Mar 10, 2018: Clinical Trials Show Strong Long-Term Performance with the Medtronic CoreValve TAVR System
6.24 Feb 15, 2018: Edwards' Self-Expanding Transcatheter Heart Valve Receives CE Mark
6.25 Feb 02, 2018: JenaValve Technology Appoints Laura A Brenton as Vice President of Clinical and International Market Development
6.26 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017
6.27 Feb 01, 2018: Edwards Lifesciences Reports Fourth Quarter Results
6.28 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region
6.29 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017
6.30 Jan 08, 2018: MicroPort CardioFlow Attends 2017 PCR-CIT China Chengdu Valves

7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact Us
7.4 Disclaimer

List of Tables
Table 1: Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Stage of Development
Table 2: Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Territory
Table 3: Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Regulatory Path
Table 4: Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Estimated Approval Date
Table 5: Transcatheter Aortic Valves Implantation (TAVI) - Ongoing Clinical Trials
Table 6: Transcatheter Aortic Valves Implantation (TAVI) Companies - Pipeline Products by Stage of Development
Table 7: Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Stage of Development
Table 8: Admedus Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Transcatheter Aortic Valve Replacement Device - Product Status
Table 10: Transcatheter Aortic Valve Replacement Device - Product Description
Table 11: Aegis Surgical Limited Pipeline Products & Ongoing Clinical Trials Overview
Table 12: pTAo-TAVR - Product Status
Table 13: pTAo-TAVR - Product Description
Table 14: AorTx, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 15: AorTx Valve - Product Status
Table 16: AorTx Valve - Product Description
Table 17: Arbor Surgical Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 18: Trilogy Aortic Valve System - Product Status
Table 19: Trilogy Aortic Valve System - Product Description
Table 20: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 21: ACURATE TAVR - Product Status
Table 22: ACURATE TAVR - Product Description
Table 23: Gen 4 Lotus Valve System - Product Status
Table 24: Gen 4 Lotus Valve System - Product Description
Table 25: Lotus Edge Sheath 15F - Product Status
Table 26: Lotus Edge Sheath 15F - Product Description
Table 27: Lotus Edge Valve System - 21 mm - Product Status
Table 28: Lotus Edge Valve System - 21 mm - Product Description
Table 29: Lotus Edge Valve System - 23 mm - Product Status
Table 30: Lotus Edge Valve System - 23 mm - Product Description
Table 31: Lotus Edge Valve System - 25 mm - Product Status
Table 32: Lotus Edge Valve System - 25 mm - Product Description
Table 33: Lotus Edge Valve System - 27 mm - Product Status
Table 34: Lotus Edge Valve System - 27 mm - Product Description
Table 35: Lotus Edge Valve System - 29 mm - Product Status
Table 36: Lotus Edge Valve System - 29 mm - Product Description
Table 37: Lotus Valve System - 21 mm - Product Status
Table 38: Lotus Valve System - 21 mm - Product Description
Table 39: Lotus Valve System - 23 mm - Product Status
Table 40: Lotus Valve System - 23 mm - Product Description
Table 41: Lotus Valve System - 25 mm - Product Status
Table 42: Lotus Valve System - 25 mm - Product Description
Table 43: Lotus Valve System - 27 mm - Product Status
Table 44: Lotus Valve System - 27 mm - Product Description
Table 45: Lotus Valve System - 29 mm - Product Status
Table 46: Lotus Valve System - 29 mm - Product Description
Table 47: Boston Scientific Corp - Ongoing Clinical Trials Overview
Table 48: Lotus Valve System - 23 mm - Experience with Percutaneous Transcatheter Aortic Valve Implantation in Patients with Symptomatic Aortic Valve Disease in Two German Centers
Table 49: Lotus Valve System - 23 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 50: Lotus Valve System - 23 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 51: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China
Table 52: Lotus Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan
Table 53: Lotus Valve System - 23 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 54: Lotus Valve System - 27 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 55: Lotus Valve System - 27 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 56: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China
Table 57: Lotus Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan
Table 58: Lotus Valve System - 27 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 59: Lotus Valve System - 25 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 60: Lotus Valve System - 25 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 61: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in China: REPRISE China
Table 62: Lotus Valve System - 25 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System - Clinical Evaluation in Japan: REPRISE Japan
Table 63: Lotus Valve System - 25 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 64: Lotus Valve System - 21 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 65: Lotus Valve System - 21 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 66: Lotus Valve System - 21 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 67: Lotus Valve System - 29 mm - Mitral Valve Replacement with the MValve Dock and a Percutaneous Transcatheter Heart Valve
Table 68: Lotus Valve System - 29 mm - Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes: RESPOND
Table 69: Lotus Valve System - 29 mm - Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis in Chinese Population (LOTUS-CHINA)
Table 70: Lotus Edge Valve System - 23 mm - Randomized Comparison of Repositionable and Balloon-Expandable Prostheses in Patients Undergoing Trans-catheter Aortic Valve Implantation
Table 71: Lotus Edge Valve System - 23 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with a Flexible Delivery System - Confirmation of Performance and Safety: REPRISE II FLEX
Table 72: Lotus Edge Valve System - 27 mm - Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve with a Flexible Delivery System - Confirmation of Performance and Safety: REPRISE II FLEX
Table 73: Carena Healthcare Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 74: PILLAR 3D Printed Replacement Heart Valve - Product Status
Table 75: PILLAR 3D Printed Replacement Heart Valve - Product Description
Table 76: Clemson University Pipeline Products & Ongoing Clinical Trials Overview
Table 77: Transcatheter Bioprosthetic Heart Valve - Product Status
Table 78: Transcatheter Bioprosthetic Heart Valve - Product Description
Table 79: Colibri Heart Valve, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 80: Colibri Aortic Heart Valve - 24mm - Product Status
Table 81: Colibri Aortic Heart Valve - 24mm - Product Description
Table 82: Colibri Aortic Heart Valve - 21mm - Product Status

List of Figures
Figure 1: Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Stage of Development
Figure 2: Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Territory
Figure 3: Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Regulatory Path
Figure 4: Transcatheter Aortic Valves Implantation (TAVI) - Pipeline Products by Estimated Approval Date
Figure 5: Transcatheter Aortic Valves Implantation (TAVI) - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Admedus Ltd
  • Aegis Surgical Limited
  • AorTx, Inc.
  • Arbor Surgical Technologies, Inc.
  • Boston Scientific Corp
  • Carena Healthcare Ltd
  • Clemson University
  • Colibri Heart Valve, LLC
  • Daidalos Solutions BV
  • Direct Flow Medical Inc
  • DSM Dyneema BV
  • Dura LLC
  • Edwards Lifesciences Corp
  • HLT, Inc.
  • JC Medical, Inc.
  • JenaValve Technology GmbH
  • Mayo Clinic
  • Medtronic plc
  • Meril Life Sciences Pvt Ltd
  • MicroPort Scientific Corp
  • PolyNova Cardiovascular LLC
  • RegenaGraft
  • ReValve Med Inc
  • SAS Cormove
  • St. Jude Medical LLC
  • Symetis SA
  • Thubrikar Aortic Valve, Inc.
  • University College London
  • University of California San Francisco
  • University of Cambridge
  • University of Iowa
  • Vascular Concepts Ltd
  • Venus MedTech
  • Xeltis AG
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll